{"entity":{"id":"ola-landgren","kind":"person","name":"C. Ola Landgren","aka":[],"tldr":"Showed that MGUS precedes essentially all myeloma and leads MRD-driven trials aiming for cure without transplant.","summary":"Ola Landgren led the prospective studies showing that monoclonal gammopathy of undetermined significance precedes virtually every case of multiple myeloma, defining the disease's precursor states, and now leads MRD-driven trials such as MANHATTAN and the daratumumab-KRd studies that achieve MRD negativity in most patients without transplant. He co-leads the international effort that made MRD an FDA-accepted endpoint.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Landgren%20O%5BAuthor%5D%20myeloma%20MRD%20OR%20MGUS"}],"tags":["myeloma","mrd","precursor"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["mrd-testing"],"targets":["cd38"],"drugs":[],"companies":[],"institutions":["sylvester-miami"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-jaiswal-chip-nejm-2014"],"journals":["jama-oncology","blood"],"dependsOn":[],"notes":[],"role":"Chief of Myeloma and Director of the Sylvester Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami","institutionId":"sylvester-miami","specialisms":["Multiple myeloma","Minimal residual disease","Precursor conditions (MGUS)","Quadruplet therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Landgren%20O%5BAuthor%5D%20myeloma%20MRD%20OR%20MGUS"}],"papers":[{"title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","journal":"Blood","year":2009,"doi":"10.1182/blood-2008-12-194241"},{"title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial","journal":"JAMA Oncology","year":2021,"doi":"10.1001/jamaoncol.2021.0611"},{"title":"Jaiswal: clonal haematopoiesis, the pre-leukaemic clones in most people over 70","journal":"New England Journal of Medicine","year":2014,"url":"https://doi.org/10.1056/NEJMoa1408617","doi":"10.1056/NEJMoa1408617"}]},"route":"/people/ola-landgren/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"target":[{"id":"cd38","kind":"target","name":"CD38","route":"/targets/cd38/"}],"institution":[{"id":"sylvester-miami","kind":"institution","name":"Sylvester Comprehensive Cancer Center, University of Miami","route":"/institutions/sylvester-miami/"}],"paper":[{"id":"paper-jaiswal-chip-nejm-2014","kind":"paper","name":"Jaiswal: clonal haematopoiesis, the pre-leukaemic clones in most people over 70","route":"/key-papers/paper-jaiswal-chip-nejm-2014/"}],"journal":[{"id":"blood","kind":"journal","name":"Blood","route":"/journals/blood/"},{"id":"jama-oncology","kind":"journal","name":"JAMA Oncology","route":"/journals/jama-oncology/"}]}}